

Filip Y F De Vos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6741680/publications.pdf>

Version: 2024-02-01

45
papers

2,462
citations

361413

20
h-index

276875

41
g-index

45
all docs

45
docs citations

45
times ranked

3709
citing authors

#	ARTICLE	IF	CITATIONS
1	The <i>EGFRvIII</i> transcriptome in glioblastoma: A meta-omics analysis. <i>Neuro-Oncology</i> , 2022, 24, 429-441.	1.2	7
2	Landscape of Driver Gene Events, Biomarkers and Druggable Targets Identified by Whole Genome Sequencing of Glioblastomas. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab177.	0.7	3
3	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , The, 2022, 23, 53-64.	10.7	165
4	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <i>TP53</i> Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	7.0	32
5	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2440-2448.	7.0	3
6	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3002-3010.	7.0	18
7	Infigratinib in Patients with Recurrent Gliomas and <i>FGFR</i> Alterations: A Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2270-2277.	7.0	30
8	Conventional MRI Criteria to Differentiate Progressive Disease from Treatment-Induced Effects in High-Grade (WHO Grade 3-4) Gliomas. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200359.	1.1	3
9	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter. <i>Neuro-Oncology</i> , 2022, 24, 1935-1949.	1.2	165
10	Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial. <i>Lancet Regional Health - Europe</i> , The, 2022, 18, 100390.	5.6	9
11	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021, 141, 945-957.	7.7	32
12	Patient-provider communication during second opinion consultations in oncology. <i>Patient Education and Counseling</i> , 2021, 104, 2490-2497.	2.2	4
13	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , 2021, 147, 1-12.	2.8	10
14	Perfusion imaging with arterial spin labeling (ASL)-MRI predicts malignant progression in low-grade (WHO grade II) gliomas. <i>Neuroradiology</i> , 2021, 63, 2023-2033.	2.2	7
15	Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2974-2983.	3.8	14
16	Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T. <i>Frontiers in Neurology</i> , 2021, 12, 718423.	2.4	9
17	Added Value of Cognition in the Prediction of Survival in Low and High Grade Glioma. <i>Frontiers in Neurology</i> , 2021, 12, 773908.	2.4	5
18	CTNI-51. ADJUVANT TROTABRESIB, A REVERSIBLE POTENT BROMODOMAIN AND EXTRATERMINAL INHIBITOR, PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS FROM A PHASE 1B DOSE-FINDING STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi71-vi72.	1.2	0

#	ARTICLE	IF	CITATIONS
19	CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548. <i>Neuro-Oncology</i> , 2021, 23, vi55-vi56.	1.2	16
20	Cancer patients' trust as a motivator to seek a second opinion and its effects on trust. <i>Psychology and Health</i> , 2021, , 1-19.	2.2	0
21	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. <i>Investigational New Drugs</i> , 2020, 38, 831-843.	2.6	71
22	Effect of a Skills Training for Oncologists and a Patient Communication Aid on Shared Decision Making About Palliative Systemic Treatment: A Randomized Clinical Trial. <i>Oncologist</i> , 2020, 25, e578-e588.	3.7	37
23	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 684-693.	1.2	126
24	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 79-89.	2.9	26
25	Reducing uncertainty: motivations and consequences of seeking a second opinion in oncology. <i>Acta Oncologica</i> , 2020, 59, 1512-1519.	1.8	6
26	Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 122, 1166-1174.	6.4	30
27	<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2466-2476.	7.0	39
28	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	7.0	27
29	Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. <i>Targeted Oncology</i> , 2019, 14, 43-55.	3.6	42
30	ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). <i>Neuro-Oncology</i> , 2019, 21, vi17-vi17.	1.2	23
31	Training for Medical Oncologists on Shared Decision-Making About Palliative Chemotherapy: A Randomized Controlled Trial. <i>Oncologist</i> , 2019, 24, 259-265.	3.7	36
32	NCMP-15. BEVACIZUMAB FOR THE TREATMENT OF CEREBRAL RADIATION NECROSIS: A RETROSPECTIVE COHORT STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi182-vi182.	1.2	0
33	ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E-MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2019, 21, vi19-vi20.	1.2	20
34	Molecular tools for the pathologic diagnosis of central nervous system tumors. <i>Neuro-Oncology Practice</i> , 2019, 6, 4-16.	1.6	8
35	Promoting shared decision making in advanced cancer: Development and piloting of a patient communication aid. <i>Patient Education and Counseling</i> , 2019, 102, 916-923.	2.2	14
36	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> -V600E-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	9.4	448

#	ARTICLE	IF	CITATIONS
37	Venous thromboembolism and intracranial hemorrhage after craniotomy for primary malignant brain tumors: a National Surgical Quality Improvement Program analysis. <i>Journal of Neuro-Oncology</i> , 2018, 136, 135-145.	2.9	50
38	Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. <i>Advances in Therapy</i> , 2018, 35, 1945-1964.	2.9	12
39	Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. <i>Journal of Neuro-Oncology</i> , 2018, 140, 485-496.	2.9	95
40	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology</i> , The, 2018, 19, 1170-1179.	10.7	80
41	Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. <i>Experimental Hematology and Oncology</i> , 2017, 6, 27.	5.0	10
42	A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. <i>Investigational New Drugs</i> , 2016, 34, 184-192.	2.6	46
43	A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI). <i>Blood</i> , 2016, 128, 4496-4496.	1.4	0
44	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. <i>European Journal of Cancer</i> , 2015, 51, 1321-1330.	2.8	45
45	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 943-953.	10.7	639